NCT04213404View on ClinicalTrials.gov

Ribociclib and Spartalizumab in R/M HNSCC

PHASE1UnknownINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 13, 2020

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2025

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Ribociclib

Ribociclib 400mg, 600mg, or 200mg oral daily, D1-D21, 28 days a cycle

DRUG

Spartalizumab

Spartalizumab 400mg ivdrip on D1, 28 days a cycle.

Trial Locations (1)

10002

National Taiwan University Hospital, Taipei

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

National Taiwan University Hospital

OTHER